AlzeCure Pharma entered into an out-licensing and collaboration agreement with QuantumCell ApS, granting QuantumCell global rights to AlzeCure's NeuroRestore platform, including its lead drug candidate ACD856.

The deal carries a total value exceeding $2.2 billion, excluding royalties, and follows the completion of a Phase Ib clinical study for ACD856 that yielded positive safety and pharmacokinetic results.¹

What are the details of the agreement?

Under the terms of the agreement, AlzeCure is set to receive a total upfront payment of $12 million, of which $5 million constitutes a direct equity investment in AlzeCure at a 30% premium to the company's 10-day average share price of SEK 3.78.¹ The remainder of the deal value is tied to set development and commercial milestone payments, as well as tiered single-digit to low double-digit royalties on sales. The transaction is subject to customary closing conditions, including approval by Swedish and Danish authorities under foreign direct investment regulations.

What Is ACD856?

ACD856 is a first-in-class small-molecule positive modulator of both NGF/TrkA and BDNF/TrkB mediated signaling, a mechanism known as Trk-PAM, that has been shown in preclinical studies to enhance communication between neurons and improve cognitive function, including learning and memory.² Preclinical work with the small-molecule also demonstrated neuroprotective, anti-inflammatory and disease-modifying effects across multiple models. The compound's mechanism enables potential use across a range of indications, including Alzheimer's disease, Parkinson's disease and depression.² ADC856 received a major grant from the European Innovation Council back in 2025, and a Phase II study in Alzheimer's patients is expected to begin in 2026.²

Johan Sandin, Chief Scientific Officer at AlzeCure Pharma, highlighted the breadth of ACD856's potential. "With the positive clinical results that we previously obtained with ACD856, as well as the preclinical results that support both cognitive enhancing abilities, neuroprotective as well as potent antidepressant effects, this is a very innovative and promising drug candidate for a wide range of indications," Sandin said.

What Did the Phase Ib Study Show?

The out-licensing agreement came on the heels of AlzeCure completing its Phase Ib clinical study of ACD856 on schedule with positive results. The study evaluated the safety and tolerability of the compound following repeated administration of higher doses than previously studied, as well as its concentration in blood and cerebrospinal fluid.²

"Consistent with previous clinical data, the results show that ACD856 was well-tolerated and no substance-related safety findings were observed," said Märta Segerdahl, Chief Medical Officer at AlzeCure Pharma. "Furthermore, an expected increase in the concentration of ACD856 was seen in both blood and cerebrospinal fluid. These data further strengthen the continued development of ACD856, broaden the therapeutic window, and provide a solid foundation for dose selection in future clinical studies."

AlzeCure had previously generated clinical data showing ACD856 crosses into the brain at relevant concentrations and activates neural pathways important for both cognition and depression, a key proof-of-mechanism milestone for a CNS drug candidate. The Phase Ib results extended those findings by establishing tolerability at higher doses, potentially widening the compound's commercial opportunity, including in depression.²

Why is the agreement important?

AlzeCure's leadership framed the transaction as validation of the company's internal drug discovery capabilities. "This first-in-class Trk-PAM drug project has been developed from idea to clinical phase in-house and shows the capabilities within AlzeCure," said CEO Martin Jönsson. "With this agreement we see the opportunity for the project's assets to earlier reach and benefit several different patient groups."

Jönsson added that the Phase Ib outcome reinforced the deal's commercial rationale. "The fact that the study progressed according to plan is excellent news, and we see that a wide therapeutic window further strengthens our commercial opportunities for this promising compound, including in other areas with very high unmet medical needs, such as depression."

Sources

1. AlzeCure Pharma enters an out-licensing and collaboration agreement with QuantumCell ApS for the NeuroRestore ACD856 project AlzeCure Pharma July 1, 2026 https://www.alzecurepharma.se/en/alzecure-pharma-enters-an-out-licensing-and-collaboration-agreement-with-quantumcell-aps-for-the-neurorestore-acd856-project/
2. Positive Results From The Phase Ib Clinical Study of NeuroRestore ACD856, Under Development for Alzheimer's Access Newswire June 16, 2026 https://finance.yahoo.com/healthcare/articles/positive-results-phase-ib-clinical-084500076.html